Positron emission tomography in chronic obstructive pulmonary disease

Poul Henning Madsen[1] MD,
Søren Hess[2] MD,
Poul Flemming Høilund-
Carlsen[2] MD, DMSc
Abass Alavi[3] MD, DSc (hon.),
PhD (hon.)

1. Department of Medicine, Division of Respiratory Medicine, Lillebælt Hospital, Denmark
2. Department of Nuclear Medicine, Odense University Hospital, Denmark
3. Division of Nuclear Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

***

Correspondence address:
Poul Henning Madsen, Sygehus Lillebælt, Medicinsk Afdeling Dronningensgade 97, 7000 Fredericia, Denmark
Email: phmadsen@dadlnet.dk
Tel: + 45 7623 70 00

Abstract

The purpose of this paper was to systematically search the literature on ^{18}F-fluorodeoxyglucose positron emission tomography (^{18}F-FDG-PET) in the management of chronic obstructive pulmonary disease (COPD) and to provide a concise review of the reported results. *Papers were searched* through PubMed, EMBASE and Cochrane Library using the MESH terms "pulmonary disease, chronic obstructive", "pulmonary emphysema", and "positron-emission tomography". Of the 38 citations from the search and from browsing the literature lists of selected articles, seven relevant reports were identified. The sparse and heterogeneous literature available *provide some indication that* ^{18}F-FDG-PET could prove useful in COPD by a) differentiating COPD from chronic asthma and alpha-1-antitrypsin deficiency, b) measuring pulmonary and systemic inflammation to guide treatment and estimate prognosis, c) quantifying respiratory muscle use, and d) diagnosing cor pulmonale. *In conclusion*, the role of ^{18}F-FDG-PET in diagnosing and managing COPD patients seems to be promising and deserves to be further studied.

Introduction

Chronic obstructive pulmonary disease (COPD) is the number four leading cause of death worldwide and hereby constitutes a major burden for patients and society. To a large extent, however, the disease is preventable, and, when correctly diagnosed, treatment options are available [1].

Diagnosis of COPD is based primarily on spirometry which typically demonstrates fixed bronchial obstruction. However, this pathophysiological measurement reflects a very broad disease spectrum ranging from predominant emphysema with destruction of alveolar septa, diffusion impairment and loss of elastic recoil to mainly bronchial inflammation with mucus production and remodeling of the airways. In addition, chronic asthma may present with fixed bronchial obstruction and constitutes a diagnostic challenge. Rarely, COPD is caused by alpha-1-antitrypsin deficiency (AATD). A common feature of all obstructive pulmonary diseases is dynamic hyperinflation, which results in excessive use of respiratory muscles to overcome the increased work of breathing. In addition, cor pulmonale is a consequence of COPD in more advanced stages. Bronchial inflammation, bronchoconstriction and dynamic hyperinflation are all important pathophysiologic components of COPD, but recently focus has been on systemic inflammation as a consequence of COPD, and patients with COPD is found to have higher levels of systemic biomarkers of inflammation [2, 3]. These patients probably have a worse cardiovascular risk profile and prognosis [4].

Basic treatment modalities in stable COPD are smoking cessation, various vaccinations, pharmacotherapy, long-term oxygen therapy and pulmonary rehabilitation. According to the latest strategy from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), treatment should be based on grading the disease severity, primarily by means of the measured forced expiratory volume in the first second (FEV_1), number of exacerbations, and by the severity of dyspnea [1]. However, an even more individually based treatment could prove valuable due to the heterogeneity of COPD. Positron emission tomography with fluorine-18-fluorodeoxyglucose (^{18}F-FDG-PET) depicting increased glucose metabolism has been studied to some degree during the last decade to demonstrate both pulmonary and systemic inflammation in COPD, to visualize respiratory muscle activity and right heart function. This paper reviews these reports.

Material and methods

We searched PubMed on March 29 2013 using the combination of the MESH terms "pulmonary disease, chronic obstructive", "pulmonary emphysema" and "positron-emission tomography". This search resulted in 34 articles, and similar searches in the EMBASE database and Cochrane Library resulted in four additional papers. We did not include ongoing studies in this review.

Of these 38 articles, 33 papers did not meet the pre-specified criteria for further review due to the following: a) topic of article was not relevant for this review (23 articles) [5-27], b) article was not an original paper (3 reviews, 3 case reports, 1 editorial) [28-34], c) only conference abstract was available (1 paper) [35], and finally d) language was non-English (2 papers) [36, 37]. Some papers fulfilled more than one exclusion criteria (e.g. non-English and not relevant).

Left for review were five articles [38-42], and a thorough search of their reference lists revealed two additional papers [43, 44].

Results

COPD and pulmonary inflammation

Jones and co-workers performed ^{18}F-FDG-PET in 6 patients with COPD (inclusion criteria FEV_1 <60% and reduced diffusion capacity), 6 patients with chronic asthma (defined by at least partially reversible airflow limitation and normal/supranormal diffusion capacity) and 5 never-smoking controls. The pulmonary ^{18}F-FDG uptake in COPD patients was significantly higher than in asthmatic and normal subjects [44]. Recently, other researchers examined 10 patients with AATD (mean FEV_1 1.7L), 10 patients with non-AATD-COPD (30%≤FEV_1<80%, mean FEV_1 1.7L), and 9 normal subjects, with ^{18}F-FDG-PET. Patients with AATD had pulmonary ^{18}F-FDG uptake comparable to normal subjects, but patients with non-AATD-COPD had a higher pulmonary ^{18}F-FDG uptake which correlated to both the level of FEV_1 and the distribution of emphysema on computed tomography [38]. Other researchers reported a study of 49 patients which were examined by diagnostic chest computed tomography and ^{18}F-FDG-PET. When corrected for the partial volume effect, they found that the degree of pulmonary inflammation (visualized by ^{18}F-FDG-PET) was correlated to the severity of emphysema, much like previous study [38], but the more recent group of researchers [42] only found this when data were corrected for partial volume effect emphasizing the importance of valid quantification strategies.

COPD and systemic inflammation

Other investigators prospectively studied aortic inflammation (as a measure of systemic inflammation) with ^{18}F-FDG-PET in 19 patients of whom 7 were ex-smokers with COPD with a mean FEV_1 of 1.2L and 7 ex-smokers without COPD (mean FEV_1 3.1). Despite similar systemic blood pressure and slightly lower mean age, the mean target-to-background ratio in the aorta was significantly higher in COPD patients than in ex-smoking patients without COPD (1.60 vs. 1.34, P=0.001). No other potential explanation for this difference was found than COPD [40].

COPD and respiratory muscle activity

One paper reported a retrospective study comprising 25 patients with COPD and 25 without COPD who had undergone ^{18}F-FDG-PET for other reasons than COPD, e.g. malignancy. The authors demonstrated a significantly increased ^{18}F-FDG uptake in respiratory muscles in all patients with COPD compared to the non-COPD patients [41]. This finding was confirmed by other researchers who retrospectively studied 26 patients without COPD and 37 with COPD in a population referred to ^{18}F-FDG-PET imaging for evaluation of lung cancer. They found increased ^{18}F-FDG uptake in both the diaphragm and intercostal muscles in 73% of the COPD patients compared to only 4% in the non-COPD group. There was no significant correlation between lung function and ^{18}F-FDG accumulation in the respiratory muscles [39].

COPD and right heart function

Other researchers reported results of a retrospective study of 14 patients with increased ^{18}F-FDG uptake in the intercostal musculature. These patients had undergone ^{18}F-FDG-PET due to various malignant diseases, but had, in addition, multiple underlying cardiorespiratory diseases including COPD. Ten had increased ^{18}F-FDG uptake in their intercostal musculature only, while 4 had also a prominent right ventricular uptake and these 4 had pulmonary hypertension confirmed by echocardiography [43].

Discussion

None of the studies described in this review were sufficiently sized to allow more general judgments on the use of ^{18}F-FDG-PET in COPD, the role of which has yet to be defined. All studies were descriptive or exploratory in nature, and, thus, their results cannot be implemented into clinical practice. Therefore, this discussion should also be considered as preliminary. However, important suggestions could be retracted from the available literature.

The first important finding was that patients with AATD and chronic asthma do not exhibit increased pulmonary ^{18}F-FDG accumulation in contrast to non-AATD-COPD patients. If confirmed by future studies, ^{18}F-FDG-PET could become valuable in distinguishing between these conditions.

The second point was that ^{18}F-FDG accumulation is highest in areas of emphysema and probably correlated to FEV_1. This could turn out important, e.g. in the planning of lung volume reduction (surgical or bronchoscopic) and for grading of disease severity.

The third important aspect was that increased systemic vascular inflammation in COPD (in the shape of enhanced aortic ^{18}F-FDG uptake) appears to be quantifiable with ^{18}F-FDG-PET. This is essential, as systemic inflammation is correlated to increased cardiovascular risk and a worse prognosis, in particular in COPD patients [4].

The fourth information from these studies was that some COPD patients exhibit increased ^{18}F-FDG accumulation in respiratory muscles as a sign of increased muscular activity. This could turn out to be useful for the triage of patients suitable for pulmonary rehabilitation and for monitoring of treatment response.

The fifth suggestive finding was that patients with cor pulmonale in COPD had a two-fold increased uptake of ^{18}F-FDG in the right ventricular wall. These patients have a worse prognosis, and the presence of cor pulmonale alters treatment strategy including the threshold for long-term oxygen therapy [1]. Whether an increased ^{18}F-FDG uptake can

be used for the diagnosis of cor pulmonale remains to be shown, but in itself it is interesting as this finding suggests a shift in right ventricular substrate preference from free fatty acids to glucose [45].

The ^{18}F-FDG-PET scan allows for a multitude of quantitative measurements. All studies in this review used quantification to some extent, some emphasizing the importance of quantifying data as compared to simple visual assessment of images. Thus, along with a clear need for further and more comprehensive studies to elucidate the role of ^{18}F-FDG-PET in the management of COPD, there is a call for an enhanced use of internationally more standardized and better validated quantitative image analysis tools [46].

In conclusion, the role of ^{18}F-FDG-PET in the management of COPD is still to be established. However, some evidence exists that a) pulmonary ^{18}F-FDG accumulation appears different in chronic asthma, AATD, and COPD, b) pulmonary ^{18}F-FDG accumulation is likely correlated to emphysema distribution and severity, c) systemic inflammation in COPD can probably be visualized and quantified by ^{18}F-FDG-PET, d) respiratory muscle use in COPD is presumably quantifiable by ^{18}F-FDG-PET, and finally e) ^{18}F-FDG-PET appears able to detect cor pulmonale.

The authors declare that they have no conflicts of interest.

Bibliography

1. Global strategy for the diagnosis, management and prevention of COPD, *Global initiative for chronic obstructive lung disease (GOLD)* 2013. Available from: http://www.goldcopd.org/. Assessed 28 March 2013.

2. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of "overspill" of inflammatory mediators from the lungs? Review of the evidence. *Thorax* 2010; 65: 930-6.

3. Karadag F, Karul AB, Cildag O et al. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. *Lung* 2008; 186: 403-9.

4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax* 2004; 59(7): 574-80.

5. Oki M, Saka H, Kitagawa C. Transesophageal bronchoscopic ultrasound-guided fine-needle aspiration for diagnosis of peripheral lung cancer. *Ann Thorac Surg* 2011; 91(5): 1613-6.

6. Mac Manus MP, Ding Z, Hogg A et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. *Int J Radiat Oncol Biol Phys* 2011; 5: 1365-71.

7. Njiaju UO, Truica CI. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. *Clin Breast Cancer* 2010; 10(1): E3-5.

8. Schaeffler F, Kos S. Solitary pulmonary nodule. *Praxis* 2009; 98(19): 1097-100.

9. Mizugaki H, Shinagawa N, Kanegae K et al. Combining transbronchial biopsy using endobronchial ultrasonography with a guide sheath and positron emission tomography for the diagnosis of small peripheral pulmonary lesions. *Lung Cancer* 2010; 68(2): 211-5.

10. Naidu SS, Rohatgi S, Herrmann HC, Glaser R. Unprotected left main "kissing" stent implantation with a percutaneous ventricular assist device. *J Invasive Cardiol* 2004; 16(11): 683-4.

11. Sebro R, Aparici CM, Hernandez-Pampaloni M. FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease. *Ann Nucl Med* 2013 [Epub ahead of print]

12. Ohno Y, Nishio M, Koyama H. Oxygen-enhanced MRI, thin-section MDCT, and perfusion SPECT/CT: comparison of clinical implications to patient care for lung volume reduction surgery. *AJR Am J Roentgenol* 2012; 199(4): 794-802.

13. Noλl-Savina E, Leroyer C, Descourt R. Delayed noninvasive reduction of large bullae following thoracic irradiation. *Clin Imaging* 2012; 36(5): 609-11.

14. Kostakis ID, Tomos P, Cholidou KG et al. Pulmonary aspergilloma: a potential cause of false positive fluorodeoxyglucose positron emission tomography scan. *Gen Thorac Cardiovasc Surg* 2012; 60(8): 528-30.

15. Furukawa M, Oto T, Yamane M et al. Spontaneous regression of primary lung cancer arising from an emphysematous bulla. *Ann Thorac Cardiovasc Surg* 2011; 17(6): 577-9.

16. Sekine A, Hagiwara E, Ogura T et al. A case of pulmonary Mycobacterium avium infection presenting multiple nodules with substantial difference in ^{18}F-fluorodeoxyglucose uptake. *Nihon Kokyuki Gakkai Zasshi* 2009; 47(7): 575-80.

17. Shapiro M, Vidal C, Lipskar AM et al. Placental transmogrification of the lung presenting as emphysema and a lung mass. *Ann Thorac Surg* 2009; 87(2): 615-6.

18. Yamada M, Goto S, Koshika M et al. Micropapillary component in lung adenocarcinoma generated in emphysema. *Kyobu Geka* 2007; 60(7): 541-5.

19. Ahmadzadehfar H, Palmedo H, Strunk H et al. False positive ^{18}F-FDG-PET/CT in a patient after talc pleurodesis. *Lung Cancer* 2007; 58(3): 418-21.

20. Aigelsreiter A, Pump A, Buchhäusl W et al. Successful antibiotic treatment of Borreliosis associated pseudolymphomatous systemic infiltrates. *J Infect* 2005; 51(4): e203-6.

21. Mattioli S, D'Ovidio F, Daddi N et al. Transthoracic endosonography for the intraoperative localization of lung nodules. *Ann Thorac Surg* 2005; 79(2): 443-9.

22. Suzuki T, Iio M, Ozawa Y et al. Regional pulmonary function in intra-emphysematous bulla and peri-emphysematous bulla. *Kokyu To Junkan* 1992; 3: 283-7.

23. Konishi J, Yamazaki K, Tsukamoto E et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. *Respiration* 2003; 70(5): 500-6.

24. Hughes JM, Rhodes CG, Brudin LH et al. Contribution of the positron camera to studies of regional lung structure and function. *Eur J Nucl Med* 1987; 13 Suppl: S37-41.

25. Murata K, Itoh H, Senda M et al. Stripe sign in pulmonary perfusion scintigraphy: central pattern of pulmonary emphysema. Work in progress. *Radiology* 1986; 160(2): 337-40.

26. Senda M, Murata K, Itoh H et al. Quantitative evaluation of regional pulmonary ventilation using PET and nitrogen-13 gas. *J Nucl Med* 1986; 27(2): 268-73.

27. Vidal Melo MF, Winkler T, Harris RS et al. Spatial heterogeneity of lung perfusion assessed with ^{13}N PET as a vascular biomarker in chronic obstructive pulmonary disease. *J Nucl Med* 2010; 51(1): 57-65.

28. Kwee TC, Torigian DA, Alavi A. Nononcological applications of positron emission tomography for evaluation of the thorax. *J Thorac Imaging* 2012; 28: 25-39.

29. Maki DD, Gefter WB, Alavi A. Recent advances in pulmonary imaging. *Chest* 1999; 116(5): 1388-402.

30. Washko GR. The role and potential of imaging in COPD. *Med*

Clin North Am 2012; 96(4): 729-43.

31. Lin FI, Foster CC, Hagge RJ, Shelton DK. Extensive FDG uptake in accessory muscles of respiration in a patient with shortness of breath. *Clin Nucl Med* 2009; 34(7): 428-30.

32. Duarte PS, Zhuang H, Machado C et al. Increased FDG uptake in the right cardiac chambers in a patient with pulmonary emphysema. *Clin Nucl Med* 2002; 27(8): 605-6.

33. Basu A, Alzeair A, Li A et al. Intercostal muscle contraction or rib bone marrow activity? *Clin Nucl Med* 2007; 32: 739-40.

34. Jones HA, Soler N. Quantification of pulmonary inflammation by positron emission tomography in chronic obstructive pulmonary disease: a new horizon in the era of biomarkers? *Am J Respir Crit Care Med* 2012; 186(11): 1071-3.

35. Chen DL, Azulay DO, Atkinson JJ et al. Reproducibility of positron emission tomography (PET)-measured [18F] fluorodeoxyglucose ([18F]FDG) uptake as a marker of lung inflammation in chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med* 2011; 183(1): A6449.

36. Sato Y, Murata K, Ito H et al. Positron emission CT and X-ray CT findings in chronic obstructive pulmonary diseases. *Rinsho Hoshasen* 1987; 32(8): 895-900.

37. Itoh H, Murata K, Senda M et al. A new imaging of pulmonary ventilation using nitrogen-13 and positron emission tomography (PET). *Kokyu To Junkan* 1987; 35(1): 21-9.

38. Subramanian DR, Jenkins L, Edgar R et al. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. *Am J Respir Crit Care* Med 2012; 186(11): 1125-32.

39. Osman MM, Tran IT, Muzaffar R et al. Does 18F-FDG uptake by respiratory muscles on PET/CT correlate with chronic obstructive pulmonary disease? *J Nucl Med Technol* 2011; 39(4): 252-7.

40. Coulson JM, Rudd JH, Duckers JM et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18F-FDG PET pilot study. *J Nucl Med* 2010; 51(9): 1357-60.

41. Aydin A, Hickeson M, Yu JQ et al. Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with chronic obstructive pulmonary disease. *Clin Nucl Med* 2005; 30(3): 159-64.

42. Torigian DA, Dam V, Chen X et al. In vivo quantification of pulmonary inflammation in relation to emphysema severity via partial volume corrected 18F-FDG-PET using computer-assisted analysis of diagnostic chest CT. *Hell J Nucl Med* 2013; 16(1): 12-8.

43. Basu S, Alzeair S, Li G et al. Etiopathologies associated with intercostals muscle hypermetabolism and prominent right ventricle visualization on 2-Deoxy-2[F-18] fluoro-D-glucose-positron emission tomography: Significance of an incidental finding and in the setting on a known pulmonary disease. *Mol Imaging Biol* 2007; 9: 333-9.

44. Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. *Eur Respir J* 2003; 21: 567-73.

45. Grynberg A, Demaison L. Fatty acid oxidation in the heart. *J Cardiovasc Pharmacol* 1996; 28: S11-7.

46. Basu S, Kwee TC, Torigian D et al. Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET. *Eur J Nucl Med Mol Imaging* 2011; 38: 1381-2.